Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
-
Patent number: 10888611Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 ?g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 ?g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.Type: GrantFiled: February 16, 2016Date of Patent: January 12, 2021Assignee: PFIZER INC.Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Rasappa Gounder Arumugham, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Thomas Richard Jones, Lakshmi Khandke, Bounthon Loun, John Lance Perez, Gary Warren Zlotnick
-
Patent number: 10889652Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: GrantFiled: June 4, 2018Date of Patent: January 12, 2021Assignee: Juno Therapeutics, Inc.Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
-
Patent number: 10882903Abstract: Methods and pharmaceutical compositions for preventing, treating or suppressing symptoms of a disorder associated with an alphavirus infection. In particular, the present invention relates to preventing, treating or suppressing symptoms of a disorder associated with an alphavirus infection through inhibiting the activity and/or expression of Transforming Growth Factor Beta (TGF-?) in a subject suffering from or at risk for suffering from an alphavirus infection.Type: GrantFiled: May 18, 2016Date of Patent: January 5, 2021Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Janko Nikolich-Zugich, Jennifer Uhrlaub
-
Patent number: 10882913Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.Type: GrantFiled: June 25, 2019Date of Patent: January 5, 2021Assignee: GENMAB B.V.Inventors: Marije Overdijk, Kristin Strumane, Rik Rademaker, Esther Breij, Janine Schuurman, Paul Parren
-
Patent number: 10874753Abstract: This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.Type: GrantFiled: September 25, 2015Date of Patent: December 29, 2020Assignees: The South African Nuclear Energy Corporation Limited, University of Cape TownInventors: Cathryn Helena Stanford Driver, Jan Rijn Zeevaart, Mohamed Iqbal Parker, Roger Hunter
-
Patent number: 10875924Abstract: Antibodies and antibody fragments that specifically bind to glycoprotein IIb/IIIa (GPIIb/IIIa) are disclosed. Chimeric molecules comprising such antibodies or antigen-binding fragments are also disclosed. In addition, methods of using the disclosed antibodies, antibody fragments, and chimeric molecules, e.g., to target agents to platelets and for the treatment or prevention of diseases or disorders are provided.Type: GrantFiled: October 23, 2015Date of Patent: December 29, 2020Assignee: Biogen MA Inc.Inventors: Joe Salas, Karl Hanf, Arjan van der Flier, Bradley R. Pearse
-
Patent number: 10875928Abstract: The present invention provides a polypeptides comprising a heavy chain domain 2 (HD2) from IgM or IgE and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis.Type: GrantFiled: July 10, 2017Date of Patent: December 29, 2020Assignee: UNIVERSITÄT STUTTGARTInventors: Roland Kontermann, Oliver Seifert, Aline Plappert
-
Patent number: 10874738Abstract: Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.Type: GrantFiled: July 13, 2016Date of Patent: December 29, 2020Assignee: IMMUNEXT INC.Inventors: Jay Rothstein, Robert George Edward Holgate, Arron Hearn
-
Patent number: 10875917Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.Type: GrantFiled: September 14, 2018Date of Patent: December 29, 2020Assignee: VITAERIS, INC.Inventor: Jeffrey T. L. Smith
-
Patent number: 10876176Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.Type: GrantFiled: December 17, 2015Date of Patent: December 29, 2020Assignees: Aravive Biologics, Inc., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Raymond Tabibiazar, Amato J. Giaccia, Mihalis Kariolis, Yu Rebecca Miao
-
Patent number: 10869924Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.Type: GrantFiled: June 15, 2016Date of Patent: December 22, 2020Assignees: MERCK PATENT GMBH, PFIZER INC.Inventors: Glen Ian Andrews, Shihao Chen, Alessandra Di Pietro, David Fontana, Zelanna Goldberg, Chia-Yang Lin, Hua Long, Marcella Martignoni, Dimitry Serge Antoine Nuyten, Aron David Thall, Adrian Woolfson
-
Patent number: 10870693Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.Type: GrantFiled: April 30, 2018Date of Patent: December 22, 2020Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Robert Joseph Stagg, Steven Eugene Benner
-
Patent number: 10864269Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.Type: GrantFiled: September 25, 2017Date of Patent: December 15, 2020Assignee: MedImmune LimitedInventors: Kris Sachsenmeier, Erin Sult, Carl Hay, Edmund Poon
-
Patent number: 10866242Abstract: The present disclosure provides sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.Type: GrantFiled: January 26, 2018Date of Patent: December 15, 2020Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL. INC.Inventors: Omid C. Farokhzad, Morteza Mahmoudi, Claudia Corbo
-
Patent number: 10864179Abstract: The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.Type: GrantFiled: September 8, 2016Date of Patent: December 15, 2020Assignee: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUISInventors: Liqin Wang, Rodrigo Leite De Oliveira, Rene Bernards
-
Patent number: 10858323Abstract: The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.Type: GrantFiled: July 3, 2018Date of Patent: December 8, 2020Assignee: REGENACY PHARMACEUTICALS, LLCInventors: Olga Golonzhka, Matthew B. Jarpe
-
Patent number: 10858686Abstract: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc region.Type: GrantFiled: June 13, 2018Date of Patent: December 8, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Terrance A. Stadheim, Dongxing Zha
-
Patent number: 10858428Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.Type: GrantFiled: September 28, 2017Date of Patent: December 8, 2020Assignees: XOMA (US) LLC, MUSC FOUNDATION FOR RESEARCH DEVELOPMENTInventors: Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
-
Patent number: 10849966Abstract: Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.Type: GrantFiled: September 18, 2018Date of Patent: December 1, 2020Assignee: TRUSTEES OF BOSTON UNIVERSITYInventors: Nelson Ruiz-Opazo, Victoria L. M. Herrera
-
Patent number: 10851178Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.Type: GrantFiled: October 10, 2012Date of Patent: December 1, 2020Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
-
Patent number: 10851164Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: GrantFiled: April 13, 2018Date of Patent: December 1, 2020Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Erik Voets, Paul Vink, David Lutje Hulsik
-
Patent number: 10844133Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.Type: GrantFiled: January 9, 2018Date of Patent: November 24, 2020Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universitat MainzInventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen
-
Patent number: 10844120Abstract: The invention provides a humanized anti-CD19 antibody or antigen binding fragment thereof comprising a light chain variable (VL) region and a heavy chain variable (VH) region in which the humanized VL and VL regions are derived from the mouse anti-CD19 clone FMC63 antibody; the humanized VL and/or humanized VH region comprise one or more amino acid substitutions in the framework region. The humanized anti-CD19 antibody or antigen binding fragment may be part of a single chain variable fragment (scFv), a chimeric antigen receptor (CAR) or a T cell receptor (TCR). Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.Type: GrantFiled: April 24, 2018Date of Patent: November 24, 2020Assignee: Kite Pharma, Inc.Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
-
Patent number: 10844123Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: GrantFiled: December 12, 2018Date of Patent: November 24, 2020Assignee: Ablynx N.V.Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
-
Patent number: 10844111Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.Type: GrantFiled: May 6, 2016Date of Patent: November 24, 2020Assignee: Janssen Biotech, Inc.Inventors: Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms
-
Patent number: 10845364Abstract: The present disclosure provides methods for measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample containing cancer cells and lymphocytes obtained from a subject by labeling lymphocytes that show CD4 expression in the sample, then labeling lymphocytes that show OX40 expression in the sample, then labeling lymphocytes that show Foxp3 expression in the sample, then measuring the number of CD4+ OX40+ Foxp3+ lymphocytes in the sample. Further provided are methods for determining the prognosis of a subject, predicting responsiveness of a subject having cancer to an OX40 agonist treatment, and methods for treating or delaying progression of cancer based on the number of CD4+ OX40+ Foxp3+ lymphocytes in a sample.Type: GrantFiled: December 21, 2017Date of Patent: November 24, 2020Assignee: Genentech, Inc.Inventors: Felix Chu, Oded Foreman, James Ziai
-
Patent number: 10844121Abstract: The present invention provides an isolated monoclonal antibody that specifically binds LAG-3. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the antibody, as well as a diagnostic and treatment method using an anti-LAG-3 antibody of the invention.Type: GrantFiled: July 12, 2018Date of Patent: November 24, 2020Assignee: NANJING LEADS BIOLABS CO., LTDInventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Lijun Zhou
-
Patent number: 10844122Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.Type: GrantFiled: May 6, 2016Date of Patent: November 24, 2020Assignee: Janssen Biotech, Inc.Inventors: Glenn Anderson, Rosa Cardoso, Michael Diem, Francois Gaudet, Shalom Goldberg, Benjamin Harman, Linus Hyun, Steven Jacobs, Donna Klein, Yingzhe Li, Jinquan Luo, Ronan McDaid, Jill Mooney, Jennifer Nemeth-Seay, Karyn O'Neil, Steven Pomerantz, Galla Chandra Rao, Tracy Spinka-Doms, Alexey Teplyakov, Leopoldo Luistro, Sheng-Jiun Wu
-
Patent number: 10836816Abstract: The combination of a first binding site specifically binding to a target associated with an eye disease and a second binding site specifically binding to a target influencing the retention in the eye a multispecific binder provides for improved intravitreal retention compared to a monospecific binder. The second binding site specifically binds to a compound/molecules found in the extracellular matrix (ECM) in vitreous humor/retina. This compound of the extracellular matrix has to be present in amounts allowing a sufficient loading/dose of the drug to be bound. It has been found that collagen, especially collagen II, is a suitable compound in the ECM in the vitreous humor for this purpose. Thus, herein is reported a multispecific binder comprising a first binding site specifically binding to a therapeutic ocular target, and a second binding site specifically binding to collagen II.Type: GrantFiled: December 4, 2018Date of Patent: November 17, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Michael Huelsmann, Erhard Kopetzki
-
Patent number: 10828370Abstract: The invention relates to peptide conjugates that can bind to endothelial cells, and that are useful for reducing the incidence and severity of endothelial dysfunction in mammals.Type: GrantFiled: May 12, 2015Date of Patent: November 10, 2020Assignee: Purdue Research FoundationInventors: Alyssa Panitch, Rebecca Scott, Kinam Park, James Wodicka
-
Patent number: 10828365Abstract: The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP).Type: GrantFiled: April 12, 2018Date of Patent: November 10, 2020Assignee: AMGEN INC.Inventors: Jane R. Parnes, Janet Griffiths
-
Patent number: 10828366Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.Type: GrantFiled: April 22, 2016Date of Patent: November 10, 2020Assignee: UCB BIOPHARMA SPRLInventors: Sam Philip Heywood, Gavin Barry Wild, Razwan Hanif, Christopher John Le Page
-
Patent number: 10829558Abstract: The present disclosure is directed to a modified isolated immunoglobulin CH2 domain that specifically binds to an extracellular region of an EphA2 receptor, wherein the amino acid sequence of the modified immunoglobulin CH2 domain includes at least one amino acid substitution, addition or deletion in comparison to a wild type immunoglobulin CH2 domain amino acid sequence, wherein the wild type immunoglobulin CH2 domain amino acid sequence includes SEQ ID NO:1 or SEQ ID NO:2. Heterologous immunoconjugates including fusion proteins and pharmaceutical compositions including the modified isolated immunoglobulin CH2 domain are also disclosed. In addition, methods of treating a disease associated with EphA2 overexpression and methods for killing a target cell expressing EphA2 receptors using the modified isolated immunoglobulin CH2 domain are provided.Type: GrantFiled: October 23, 2015Date of Patent: November 10, 2020Assignee: RESEARCH CORPORATION TECHNOLOGIES, INC.Inventors: Kurt R. Gehlsen, Licia Tomei, Anna Demartis
-
Patent number: 10828318Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.Type: GrantFiled: January 5, 2017Date of Patent: November 10, 2020Assignee: Yeda Research and Development Co. Ltd.Inventors: Idit Shachar, Hadas Lewinsky, Lihi Radomir, Anna Wiener
-
Patent number: 10821161Abstract: Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.Type: GrantFiled: December 7, 2015Date of Patent: November 3, 2020Assignee: City of HopeInventors: Xiuli Wang, Stephen J. Forman
-
Patent number: 10822399Abstract: The present invention concerns IgA multi-specific binding molecules. In particular, the invention concerns multi-specific, including bispecific, binding molecules comprising IgA heavy chain sequences, and methods for their preparation and use.Type: GrantFiled: February 10, 2015Date of Patent: November 3, 2020Assignee: IGM Biosciences, Inc.Inventors: Bruce Keyt, Leonard George Presta, Fen Zhang, Stephen F. Carroll
-
Patent number: 10822429Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, with substantial reduction in sub-visible particles, and methods of manufacture of these compositions, methods of administration, and articles of manufacture.Type: GrantFiled: January 8, 2015Date of Patent: November 3, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Brian Murphy, Douglas Farrar, Alan Herman
-
Patent number: 10822411Abstract: In the methods of the invention, an agent that increases phagocytosis and/or efferocytosis of cellular components of coronary plaque is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce aneurysm disease in the individual.Type: GrantFiled: September 9, 2015Date of Patent: November 3, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Nicholas J. Leeper, Irving L. Weissman
-
Patent number: 10815304Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.Type: GrantFiled: November 2, 2016Date of Patent: October 27, 2020Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
-
Patent number: 10806787Abstract: The present invention provides an anti-FSTL1 antibody or a fragment or functional equivalent thereof, wherein the antibody recognizes an epitope in a region selected from the group consisting of amino acid positions 48 to 100, 148 to 162, 193 to 216, 205 to 228, and 272 to 289 of SEQ ID NO: 1 (amino acid sequence of human FSTL1). The present invention also provides a combination product of a FSTL1 suppressor and additional cancer treatment. It is understood that immune defect such as immunosuppression or immunodeficiency is effectively mitigated by the present invention.Type: GrantFiled: February 16, 2016Date of Patent: October 20, 2020Assignee: PHARMA FOODS INTERNATIONAL CO., LTD.Inventors: Chie Kudo, Masayoshi Toyoura, Akiko Ishida, Yuji Shoya, Chihiro Yamazaki
-
Patent number: 10808036Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.Type: GrantFiled: June 5, 2017Date of Patent: October 20, 2020Assignee: GENENTECH, INC.Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
-
Patent number: 10800844Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: October 28, 2016Date of Patent: October 13, 2020Assignee: ALECTOR LLCInventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
-
Patent number: 10803586Abstract: A method of facilitating image analysis in pathology involves receiving a sample image representing a sample for analysis, the sample image including sample image elements, causing one or more functions to be applied to the sample image to determine a plurality of property specific confidence related scores, each associated with a sample image element and a respective sample property and representing a level of confidence that the associated element represents the associated sample property, sorting a set of elements based at least in part on the confidence related scores, producing signals for causing one or more of the set of elements to be displayed to a user in an order based on the sorting, for each of the one or more elements displayed, receiving user input, and causing the user input to be used to update the one or more functions. Other methods, systems, and computer-readable media are disclosed.Type: GrantFiled: February 12, 2020Date of Patent: October 13, 2020Assignee: AIFORIA TECHNOLOGIES OYInventors: Juha Reunanen, Liisa-Maija Keinänen, Tuomas Ropponen
-
Patent number: 10800842Abstract: An anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold, pharmaceutical compositions containing them and uses therefor.Type: GrantFiled: September 20, 2018Date of Patent: October 13, 2020Assignee: ADRENOMED AGInventor: Andreas Bergmann
-
Patent number: 10799583Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.Type: GrantFiled: February 2, 2018Date of Patent: October 13, 2020Assignee: UCB PHARMA, S.A.Inventor: Martyn K. Robinson
-
Patent number: 10793628Abstract: Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed. The invention also relates to antisense, RNAi and shRNA compositions for the prevention and treatment of cancer, in particular breast cancer and pancreatic cancer.Type: GrantFiled: June 30, 2015Date of Patent: October 6, 2020Assignee: Academia SinicaInventors: Wen-Hwa Lee, Jin-Yuh Shew, Che Ma, Chia-Lin Chen, Wen-Hsin Lee, Chun-Kai Huang, Heng-Hsiung Wu
-
Patent number: 10793623Abstract: The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.Type: GrantFiled: May 11, 2018Date of Patent: October 6, 2020Assignee: The University of North Carolina at Chapel HillInventors: Samuel Lai, M. Gregory Forest, Christine Henry, Timothy Wessler, Alexander Chen, Jennifer Schiller, Jay Newby
-
Patent number: 10793641Abstract: The present invention provides fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin.Type: GrantFiled: August 22, 2016Date of Patent: October 6, 2020Assignee: CARSGEN THERAPEUTICS CO., LTD.Inventors: Huamao Wang, Bo Song, Peng Wang
-
Patent number: 10786578Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: GrantFiled: July 27, 2015Date of Patent: September 29, 2020Assignee: Novartis AGInventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
-
Patent number: 10787518Abstract: The present invention is directed to compositions that include programmed cell death 1 (PD-1) binding domains and antibodies that include such PD-1 binding domains. Also provided are nucleic acid compositions that encode the binding domains and antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.Type: GrantFiled: June 14, 2017Date of Patent: September 29, 2020Assignee: Xencor, Inc.Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal